CANNABINOID ASSAY AND THE RANDOX CANNABINOID CALIBRATOR/ CONTROL SET

K092269 · Randox Laboratories, Ltd. · LDJ · Apr 8, 2011 · Clinical Toxicology

Device Facts

• Record ID: K092269
• Device Name: CANNABINOID ASSAY AND THE RANDOX CANNABINOID CALIBRATOR/ CONTROL SET
• Applicant: Randox Laboratories, Ltd.
• Product Code: LDJ · Clinical Toxicology
• Decision Date: Apr 8, 2011
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3870
• Device Class: Class 2

Indications for Use

The Randox Laboratories Ltd. Cannabinoid Assay is an in vitro diagnostic test for the detection of 11-nor-Δ9-THC-9-COOH (THC) in human urine with a cut off concentration of 50ng/ml, for use on the Rx Imola and Rx Daytona analyzers in qualitative or semi-quantitative mode. This in vitro diagnostic device is intended for prescription use only. The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS or (2) permitting laboratories to establish quality control procedures. This assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas chromatograph/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. The Randox Cannabinoid Calibrator Set consists of liquid calibrators containing 11-nor-Δ9-THC-9-COOH (THC). There are 5 levels of calibrator. They have been developed for use in the calibration of THC assays on the Rx Imola and Rx Daytona analyzers. This in vitro diagnostic device is intended for prescription use only. The Randox Cannabinoid Controls, level 1 and 2 are liquid controls containing 11-nor-Δ9-THC-9-COOH (THC). There are 2 levels of controls. They have been developed for use in the quality control of the THC assay on the Rx Imola and Rx Daytona analyzers. This in vitro diagnostic device is intended for prescription use only.

Device Story

Randox Cannabinoids Assay is an in vitro diagnostic test for detecting 11-nor-d-THC-9-COOH in human urine. Used on Rx imola and Rx Daytona analyzers in clinical laboratory settings by trained personnel. Assay provides preliminary results; requires confirmation via GC/MS. Includes liquid calibrators (5 levels) and controls (2 levels) for system calibration and quality control. Healthcare providers use results to guide clinical decisions, necessitating professional judgment for positive findings. Benefits include rapid preliminary screening for cannabinoids to facilitate subsequent confirmatory testing.

Clinical Evidence

No clinical data provided. Bench testing only.

Technological Characteristics

In vitro diagnostic assay for human urine. Analyte: 11-nor-d-THC-9-COOH. Cutoff: 50ng/ml. Form factor: Liquid reagents, calibrators, and controls. Analyzers: Rx imola and Rx Daytona. Principle: Immunochemical detection. Intended for prescription use.

Indications for Use

Indicated for the detection of 11-nor-Δ9-THC-9-COOH in human urine at a 50ng/ml cutoff. Intended for prescription use in clinical laboratories on Rx Imola and Rx Daytona analyzers. Provides preliminary results requiring confirmation by GC/MS.

Regulatory Classification

Identification

A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds include delta-9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use.

Special Controls

*Classification.* Class II (special controls). A cannabinoid test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Submission Summary (Full Text)

{0}

1

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE

A. 510(k) Number:
k092269

B. Purpose for Submission:
New assay

C. Measurand:
Tetrahydrocannabinol

D. Type of Test:
Homogeneous enzyme immunoassay – qualitative and semi-quantitative

E. Applicant:
Randox Laboratories Ltd.

F. Proprietary and Established Names:
Cannabinoid Assay

G. Regulatory Information:
1. Regulation section:
21 CFR 862.3870, Cannabinoid Test System, 21CFR 862.1150, Calibrator, 21 CFR 862.1660, Quality Control Material
2. Classification:
Class II, II and I, respectively
3. Product code:
LDJ, JIT, JJX
4. Panel:
Toxicology (91)

{1}

H. Intended Use:

1. Intended use(s):
See Indications for use, below.

2. Indication(s) for use:
The Randox Laboratories Ltd. Cannabinoid Assay is an in vitro diagnostic test for the detection of 11-nor-Δ9-THC-9-COOH (THC) in human urine with a cut off concentration of 50ng/ml, for use on the Rx Imola and Rx Daytona analyzers in qualitative or semi-quantitative mode. This in vitro diagnostic device is intended for prescription use only.

The semi-quantitative mode is for purposes of
(1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS or
(2) permitting laboratories to establish quality control procedures

This assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas chromatograph/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

The Randox Cannabinoid Calibrator Set consists of liquid calibrators containing 11-nor-Δ9-THC-9-COOH (THC). There are 5 levels of calibrator. They have been developed for use in the calibration of THC assays on the Rx Imola and Rx Daytona analyzers. This in vitro diagnostic device is intended for prescription use only.

The Randox Cannabinoid Controls, level 1 and 2 are liquid controls containing 11-nor-Δ9-THC-9-COOH (THC). There are 2 levels of controls. They have been developed for use in the quality control of the THC assay on the Rx Imola and Rx Daytona analyzers. This in vitro diagnostic device is intended for prescription use only.

3. Special conditions for use statement(s):
For prescription use only.

4. Special instrument requirements:
The assay has been developed for use on the Rx Daytona™, and Rx Imola™.

2

{2}

3

I. Device Description:

The assay consists of two reagent bottles supplied ready for use. R-1 contains monoclonal 11-nor-Δ9-THC-9-COOH antibodies, glucose-6-phosphate (G6P), nicotinamide adenine dinucleotide NAD, stabilizers, and sodium azide <0.1% w/v. R-2 is an enzyme-drug conjugate reagent containing buffer, Δ9-THC-9-COOH-labelled G6PDH, and sodium azide, <0.1% w/v.

Calibrators and control materials are liquid ready to use containing 11-nor-Δ⁹-THC-9-COOH at levels of (0, 20, 50, 100, 200 ng/mL) for the calibrator and 37.5 and 62.5 ng/ml for the control material.

J. Substantial Equivalence Information:

1. Predicate device name(s):
Microgenics DRI Cannabinoid Assay, Calibrators and Controls.

2. Predicate 510(k) number(s):
k943998

3. Comparison with predicate:
See the table below. The intended use and test principle are the same for both assays.

| ITEM | Randox Cannabinoid Assay k092269 | Microgenics DRI Cannabinoid Assay k943998 |
| --- | --- | --- |
| | | |
| Intended Use | Qualitative and semi-quantitative analysis Cannabinoids in human urine | Same |
| Cutoff | 50 ng/mL | 20, 50 or 100 ng/mL |
| Test Principle | A homogeneous enzyme immunoassay based on competition between drug in the sample and drug labelled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). | Same |
| Sample type | Human urine | Same |
| Type of reagent | Liquid Ready to use Two reagent assay | Same |
| | | |
| Calibrators – intended use | For THC assay calibration | Same |

{3}

4

| Calibrators – format | Liquid ready to use (0, 20, 50, 100, 200 ng/mL) | Liquid ready to use (20, 50, 100, 200 ng/mL) |
| --- | --- | --- |
| Controls – intended use | For THC assay quality control | Same |
| Controls –format | Liquid ready to use 37.5, 62.5 ng/ml | Liquid ready to use 40, 60, 75, 125 ng/mL |

## K. Standard/Guidance Document Referenced (if applicable):

None were referenced.

## L. Test Principle:

The assay is a homogeneous enzyme immunoassay with ready-to-use liquid reagent. The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. In the absence of drug in the sample, the antibody binds the conjugated G6PDH-THC $\Delta^9$ thus the enzyme activity is inhibited. When free drug is present on the sample, the antibody will bind to the free drug and the unbound G6PDH-conjugated drug exhibits its maximal enzyme activity. The G6PDH activity is measured spectrophotometrically at $340\mathrm{nm}$ due to conversion of NAD to NADH by the active enzyme.

## M. Performance Characteristics (if/when applicable):

### 1. Analytical performance:

Performance was evaluated on the Rx Daytona™, and Rx Imola™.

#### a. Precision/Reproducibility:

Negative urine samples spiked with 11-nor-9-carboxy-$\Delta$9-THC were evaluated. Samples contained the following concentrations relative to the $200\mathrm{ng/mL}$ cut-off: +/-25%, +/-50%, +/-75% and +/-100%. Samples were tested in random order on two Rx Daytona systems and two Rx Imola systems twice per day for 20 non-consecutive days. Calibrations were carried out twice throughout the duration. Results are shown below.

Rx Daytona Semi-Quantitative

| THC concentration (% cutoff) | No. of determinations | Results #Neg/#Pos |
| --- | --- | --- |
| -100 | 80 | 80 Neg |
| -75 | 80 | 80 Neg |
| -50 | 80 | 80 Neg |
| -25 | 80 | 80 Neg |

{4}

| +25 | 80 | 80 Pos |
| --- | --- | --- |
| +50 | 80 | 80 Pos |
| +75 | 80 | 80 Pos |
| +100 | 80 | 80 Pos |

Identical results were obtained for semi-quantitative and qualitative results on both the Imola and the Daytona Instruments.

# b. Linearity/assay reportable range:

A drug free urine pool was spiked with pure secobarbital. A $100\mathrm{ng / mL}$ sample was further diluted in increments of $10\%$ to a concentration of $10\mathrm{ng / mL}$ . Samples were tested in semi-quantitative mode in a random order in triplicate. Results are shown below.

| Expected Concentration (ng/mL) | Imola Result (ng/mL) | Percent recovery Rx Imola | Daytona result (ng/mL) | Percent recovery Rx Daytona |
| --- | --- | --- | --- | --- |
| 0 | 15.3 | N/A | 6.5 | N/A |
| 2 | 12.8 | 641 | 5.2 | 259 |
| 4 | 15.0 | 374 | 8.2 | 205 |
| 6 | 10.1 | 168 | 13.3 | 221 |
| 8 | 19.4 | 242 | 10.4 | 129 |
| 10 | 16.3 | 163 | 11.3 | 113 |
| 12 | 14.8 | 124 | 17.2 | 143 |
| 14 | 12.9 | 92 | 15.9 | 114 |
| 16 | 16.7 | 104 | 23.1 | 144 |
| 18 | 20.0 | 111 | 26.3 | 146 |
| 20 | 22.5 | 113 | 18.8 | 94 |
| 40 | 39.2 | 98 | 42.5 | 106 |
| 60 | 58.4 | 97 | 63.0 | 105 |
| 80 | 73.9 | 92 | 83.9 | 105 |
| 100 | 94.8 | 95 | 100.6 | 101 |
| 140 | 148.5 | 106 | 151.2 | 108 |
| 200 | 193.7 | 97 | 210.6 | 105 |

# c. Traceability, Stability, Expected values (controls, calibrators, or methods):

# Traceability:

THC calibrators and THC controls are both traceable to GC/MS quantified master lots. The master lots are prepared by spiking 11-nor- $\Delta^9$ -THC-9-COOH at the appropriate levels into a buffered human urine matrix that also contains $0.05\%$ sodium azide by gravimetric preparation using balances calibrated with NIST traceable weights. Purity of material used for spiking is determined using GC/FID, HPLC and NMR. Value assignment for control materials and

{5}

calibrator materials is determined against the current master lot by performing nested testing of the new control materials and the new calibrator materials. The new lots are analyzed in replicates of 10. Results need to meet the sponsor's pre-determined acceptance criteria %CV and % recovery against the current master lot.

The estimated un-certainty in the calibrator value assignments is shown below.

| Calibrator Level | Target Value (ng/mL) | Total Uncertainty (ng/mL) |
| --- | --- | --- |
| 1 | 20 | +/- 8.51 |
| 2 | 50 | +/- 5.65 |
| 3 | 100 | +/- 5.99 |
| 4 | 200 | +/- 7.93 |

## Stability

To determine a shelf-life claim for the THC calibrators and THC controls, materials stored at +2-8°C are tested at multiple time points up to 18 months. The assay is calibrated at each time point with known stable calibrators, and controls are tested. The recoveries achieved at each time-point are compared to those achieved at Day 0 and must fall within the sponsor's predetermined acceptance criteria. Open vials of control materials and calibrator materials are stable for 28 days at 2-8°C.

Real time stability studies up to nine months were included in the 510(k). No decrease in stability was observed over nine months.

## d. Detection limit:

Performance at low drug concentration in the semi-quantitative assay was characterized by determination of the lowest concentration of drug that is capable of producing a positive result. This concentration was sufficiently below the claimed cutoff.

## e. Analytical specificity:

Interference and cross-reactivity studies were carried out in the qualitative and semi-quantitative modes to evaluate potential cross-reactive compounds, potential interfering compounds including structurally related compounds and potentially interfering endogenous compounds. Test compounds were spiked into GC/MS verified negative urine and into GC/MS verified urine spiked at cannabinoid concentrations +/-25% of the assay cut-off. Replicates of each

{6}

sample were measured, and evaluated against the cut-off calibrator (50ng/mL).

Results of cross-reactivity studies are shown in the table below:

| Compound | Range of percents cross-reactivity observed. |
| --- | --- |
| 11-norΔ9-THC-9-COOH | 100% |
| 11-OH- Δ9-THC | 18-36% |
| Cannabidiol | <1% |
| Δ9-THC | 10-24% |

Endogenous compounds

No interference was observed (in either semi-quantitative or qualitative mode on either instrument) from the substances below at the concentrations shown.

| Compound | Tested Conc. (mg/dL) |
| --- | --- |
| Total Bilirubin | 15 |
| Direct Bilirubin | 5 |
| Hemoglobin | 115 |
| Creatinine | 30 |
| Urea | 258 |
| Glucose | 2000 |
| H.S.A. | 500 |
| Ethanol | 1000 |
| Acetone | 1000 |
| Gamma globulin | 500 |
| Oxalic acid | 100 |
| Riboflavin | 7.5 |
| Sodium chloride | 6000 |
| Boric acid | 1000 |
| Sodium azide | 1000 |
| Sodium fluoride | 1000 |

Studies examining the effects on performance of variations in pH and specific gravity were also carried out. Specific gravity was tested across the range of 1.000 – 1.030 and pH across the range of 3 – 11 and no interference was observed.

Commonly co-administered prescription and OTC compounds:

{7}

The potential effect of other compounds on the recovery of cannabinoid using the Randox Cannabinoid assay was assessed. The complete list of compounds tested is shown in the package insert. No interference was observed.

f. Assay cut-off:

See Detection Limit Section, above. The claimed assay cutoff is 50 ng/mL.

2. Comparison studies:

a. Method comparison with predicate device:

Urine samples obtained from a clinical laboratory where they had been tested by GC/MS for the presence or absence of THC were assayed on the Daytona and Imola instruments in qualitative and semi-quantitative mode. Results are shown in the tables below:

| | Neg by GCMS | Less than half the cut-off conc. by GC/MS | Between 50% below the cutoff and the cutoff conc. | Between the cutoff and 50% above the cutoff conc. | Greater than 50% above the cutoff conc. | % Agreement with GC/MS |
| --- | --- | --- | --- | --- | --- | --- |
| Daytona Semi-quantitative | | | | | | |
| Positive | 0 | 2 | 17 | 35 | 69 | 83.3% |
| Negative | 75 | 3 | 17 | 2 | 0 | 98.1% |

The list of discrepant results is shown in the table below.

| Daytona Semi-Quantitative | Drug GC/MS value (ng/mL) |
| --- | --- |
| POS | 18 |
| POS | 21 |
| POS | 25 |
| POS | 31 |
| POS | 32 |
| POS | 34 |
| POS | 35 |
| POS | 38 |
| POS | 38 |

{8}

| POS | 41 |
| --- | --- |
| POS | 41 |
| POS | 41 |
| POS | 42 |
| POS | 43 |
| POS | 44 |
| POS | 44 |
| POS | 47 |
| POS | 48 |
| POS | 48 |
| NEG | 50 |
| NEG | 52 |
| Daytona qualitative | Neg | Less than half the cut-off conc. by GC/MS | Between 50% below the cutoff and the cutoff conc. | Between the cutoff and 50% above the cutoff conc. | Greater than 50% above the cutoff conc. | % Agreement with GC/MS |
| --- | --- | --- | --- | --- | --- | --- |
| Positive | 0 | 2 | 17 | 33 | 69 | 83.3% |
| Negative | 75 | 3 | 17 | 4 | 0 | 96.2% |

The list of discrepant results is shown in the table below.

| Daytona Qualitative | Drug/ Metabolite GC/MS value (ng/mL) |
| --- | --- |
| POS | 18 |
| POS | 21 |
| POS | 25 |
| POS | 31 |
| POS | 32 |
| POS | 34 |
| POS | 35 |
| POS | 38 |
| POS | 38 |
| POS | 41 |
| POS | 41 |
| POS | 42 |
| POS | 43 |

{9}

| POS | 44 |
| --- | --- |
| POS | 44 |
| POS | 47 |
| POS | 48 |
| POS | 48 |
| NEG | 50 |
| NEG | 52 |
| NEG | 52 |
| NEG | 53 |
| Imola Semi-quantitative | Neg | Less than half the cutoff conc. by GC/MS | Between 50% below the cutoff and the cutoff conc. | Between the cutoff and 50% above the cutoff conc. | Greater than 50% above the cutoff conc. | % Agreement with GC/MS |
| --- | --- | --- | --- | --- | --- | --- |
| Positive | 0 | 2 | 16 | 33 | 69 | 86.0% |
| Negative | 75 | 3 | 18 | 4 | 0 | 96.2% |

The list of discrepant results is shown in the table below.

| IMOLA Semi-Quantitative | Drug GC/MS value (ng/mL) |
| --- | --- |
| POS | 18 |
| POS | 21 |
| POS | 25 |
| POS | 31 |
| POS | 32 |
| POS | 34 |
| POS | 35 |
| POS | 38 |
| POS | 38 |
| POS | 41 |
| POS | 41 |
| POS | 42 |
| POS | 43 |
| POS | 44 |
| POS | 44 |
| POS | 47 |

{10}

| POS | 48 |
| --- | --- |
| POS | 48 |
| NEG | 50 |
| NEG | 52 |
| NEG | 52 |
| NEG | 64 |
| Imola qualitative | Neg | Less than half the cutoff conc. by GC/MS | Between 50% below the cutoff and the cutoff conc. | Between the cutoff and 50% above the cutoff conc. | Greater than 50% above the cutoff conc. | % Agreement with GC/MS |
| --- | --- | --- | --- | --- | --- | --- |
| Positive | 0 | 2 | 16 | 33 | 69 | 86.0% |
| Negative | 75 | 3 | 18 | 4 | 0 | 96.2% |

The list of discrepant results is shown in the table below.

| Imola qualitative | Drug/Metabolite GC/MS value (ng/mL) |
| --- | --- |
| POS | 18 |
| POS | 21 |
| POS | 25 |
| POS | 31 |
| POS | 32 |
| POS | 34 |
| POS | 35 |
| POS | 38 |
| POS | 38 |
| POS | 41 |
| POS | 41 |
| POS | 42 |
| POS | 43 |
| POS | 44 |
| POS | 44 |
| POS | 47 |
| POS | 48 |
| POS | 48 |
| NEG | 50 |

{11}

| NEG | 52 |
| --- | --- |
| NEG | 52 |
| NEG | 64 |

Additional information was submitted by the sponsor to support that positive readings for samples with GCMS values below 25 ng/mL were due to metabolites.

b. Matrix comparison: Not applicable. The test is only for urine specimens.

3. Clinical studies:

a. Clinical Sensitivity: Not typically reviewed for this device type.
b. Clinical specificity: Not typically reviewed for this device type.
c. Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off: Not typically reviewed for this type of test. The analytical cutoff is 50 ng/mL

5. Expected values/Reference range:

Not applicable.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.